| |
 Dr.
Max is Chief of the Clinical Trials Unit, Pain and Neurosensory
Mechanisms Branch, National Institute of Dental and Craniofacial
Research, NIH, in Bethesda, Maryland. After graduating from
Harvard Medical School in 1974, Dr. Max completed residencies
in internal medicine at the University of Chicago and neurology
at the New York Hospital, followed by a fellowship in clinical
pharmacology and cancer pain treatment at Memorial Sloan-Kettering
Cancer Center with Dr. Kathleen Foley, whom he assisted
in the development of the World Health Organization's Cancer
Pain Relief Program. Dr. Max has been at the NIH since 1983,
where his major research interests have been
ANALGESIC
CLINICAL TRIALS AND THE CLINICAL GENETICS OF CHRONIC PAIN.
The
studies of Dr. Max and his NIDCR colleagues have demonstrated
the effectiveness of norepinephrine reuptake blockers, adrenergic
agonists, and NMDA receptor antagonists in neuropathic pain
and AMPA/kainate receptor blockade in hyperalgesia, and
have introduced methods for clinical trials in patients
with chronic pain. Dr. Max is the editor of the standard
textbook, The Design of Analgesic Clinical Trials and the American
Pain Society's Principles of Analgesic Use and Quality
Improvement Standards for the Treatment of Acute Pain and
Cancer Pain, and is on the editorial board of Pain,
Neurology, and other journals. Dr. Max's research
has been recognized by a number of honors, including the
Public Health Service Citation and Commendation Medals and
the American Pain Society's Wilbert Fordyce Award for Clinical
Investigation.
|